Literature DB >> 11455984

Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour.

M H Bakkus1, K Asosingh, K Vanderkerken, K Thielemans, A Hagemeijer, H De Raeve, B Van Camp.   

Abstract

Isotype-switch variants can easily be detected in a significant proportion of multiple myeloma (MM) patients. The biological significance of these isotype-switch variants remains obscure. Therefore, we studied the appearance of these isotype-switch variants in two murine MM models, 5T2MM and 5T33MM, both of IgG isotype. With a MM-specific PCR assay we could detect isotype-switch variants in the bone marrow of both the 5T2MM and the 5T33MM bearing mice, reflecting again the close resemblance of this mouse model to the human MM. These isotype-switch variants were not found in an in vitro stroma-independent variant of the 5T33MM line. However, when this 5T33MMvitro line was injected into young syngeneic mice, isotype-switch variants appeared thereafter in the isolated tumour cells. These isotype-switch variants could only originate from the MM-IgG expressing cell since IgG subclones from the 5T33MMvitro line again gave rise to isotype-switch variants. The appearance of IgA cells can be explained by down-stream switching of IgG to IgA, while the emergence of IgM cells have to occur via trans-switching to the sister chromatid as the Cmu region is deleted from the CIS-chromosome. This study demonstrates that isotype-switch variants originate from the major tumour clone suggesting no role for the MM-IgM expressing cell as a pre-switch precursor MM cell. The appearance of isotype-switch variants should be considered as a rare but normal event now becoming visible due to the high number of clonal cells present in MM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455984     DOI: 10.1038/sj.leu.2402164

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  4 in total

1.  Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.

Authors:  Pramod S Gowda; Benjamin J Wildman; Timothy N Trotter; Xiaoxuan Xu; Xiaoxiao Hao; Mohammad Q Hassan; Yang Yang
Journal:  Mol Cancer Res       Date:  2018-03-28       Impact factor: 5.852

2.  Myeloma cell-derived Runx2 promotes myeloma progression in bone.

Authors:  Timothy N Trotter; Mei Li; Qianying Pan; Deniz Peker; Patrick D Rowan; Juan Li; Fenghuang Zhan; Larry J Suva; Amjad Javed; Yang Yang
Journal:  Blood       Date:  2015-04-10       Impact factor: 22.113

3.  Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging.

Authors:  Babatunde O Oyajobi; Steve Muñoz; Rami Kakonen; Paul J Williams; Anjana Gupta; Christi L Wideman; Beryl Story; Barry Grubbs; Allison Armstrong; William C Dougall; I Ross Garrett; Gregory R Mundy
Journal:  Mol Cancer Ther       Date:  2007-05-31       Impact factor: 6.261

4.  Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma.

Authors:  Martin Trepel; Victoria Martens; Christian Doll; Janina Rahlff; Barbara Gösch; Sonja Loges; Mascha Binder
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.